EMEA-003581-PIP01-24 - paediatric investigation plan

derivative of 1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one

Key facts

• Active Substance:
  derivative of 1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
• Therapeutic area:
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
• Decision number:
  P/0209/2024
• PIP number:
  EMEA-003581-PIP01-24
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of lung cancer (small cell and non-small cell lung cancer)
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  14/06/2024

Decision

P/0209/2024 : EMA decision of 14 June 2024 on the granting of a product specific waiver for derivative of 1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (EMEA-003581-PIP01-24)

AdoptedReference Number: EMA/234752/2024